Background and aims: Lack of achievement of secondary prevention objectives in patients with ischaemic heart disease remains an unmet need in this patient population. We aimed at evaluating the six-month efficacy of an intensive lipid-lowering intervention, coordinated by nurses and implemented after hospital discharge, in patients hospitalized for an ischaemic heart disease event. Methods: Randomized controlled trial, in which a nurse-led intervention including periodic follow-up, serial lipid level controls, and subsequent optimization of lipid-lowering therapy, if appropriate, was compared with standard of care alone in terms of serum lipid-level control at six months after discharge. Results: The nurse-led intervention was associated with an improved management of low-density lipoprotein (LDL) cholesterol levels compared with standard of care alone: LDL cholesterol levels ⩽100 mg/dL were achieved in 97% participants in the intervention arm as compared with 67% in the usual care arm (p value <0.001), the LDL cholesterol ⩽70 mg/dL target recommended by the 2016 European Society of Cardiology guidelines was achieved in 62% vs. 37% participants (p value 0.047) and the LDL cholesterol reduction of ⩾50% recommended by the American College of Cardiology/American Heart Association in 2013 was achieved in 25.6% of participants in the intervention arm as compared with 2.6% in the usual care arm (p value 0.007). The intervention was also associated with improved blood pressure control among individuals with hypertension. Conclusions: Our findings highlight the opportunity that nurse-led, intensive, post-discharge follow-up plans may represent for achieving LDL cholesterol guideline-recommended management objectives in patients with ischaemic heart disease. These findings should be replicated in larger cohorts.
Introduction
Despite landmark primordial and primary preventive efforts, 1,2 as well as dramatic improvements in the acutephase care of ischaemic heart disease (IHD) patients attained in the last three decades, [3] [4] [5] IHD remains one of the leading causes of death worldwide. 5 Among the prevailing unmet needs in the care of these patients, lack of achievement of secondary prevention targets after an acute IHD event is currently considered a key issue. 6, 7 Specifically, although the guidelines of the European Society of Cardiology (ESC) recommend that patients with overt IHD should be treated aggressively to achieve lowdensity lipoprotein (LDL) cholesterol levels ⩽70 mg/dL, 6, 8 this treatment goal is often not achieved. 6, 7 Poor adherence to lifestyle recommendations and pharmacological therapies by patients, as well as time constrains, limited followup and medication titration by healthcare providers are considered important participating factors. [9] [10] [11] [12] Studies suggest that specialized post-discharge followup by trained nurses represents an opportunity to improve the care and outcomes of patients with cardiovascular diseases. [13] [14] [15] Nurses may have more availability than physicians to conduct close follow-up, and may communicate with patients more effectively, particularly in terms of health education. Specifically, periodic follow-up by specialized nurses has become a key component of chronic disease management programmes for patients with chronic diseases, such as heart failure. 13 However, whether this approach may also be beneficial for patients with IHD is less understood.
Our aim was thus to evaluate the six-month efficacy of an intensive lipid-lowering intervention, coordinated by a nurse and implemented after hospital discharge, in patients hospitalized for an IHD event. For this purpose, we conducted a randomized, controlled trial in which this intervention was compared with the standard of care, in terms of use of lipid-lowering therapies and lipid-level control at six months after discharge.
Materials and methods

Study context
Since 2007, a multi-disciplinary cardiac rehabilitation programme (CRP) has been in place in our centre. The CRP is coordinated by specialized nurses, and includes interventions performed by cardiologists, nurses, rehabilitation physicians, physiotherapists and professionals specialized in the management of anxiety and other mental health disorders. All patients discharged from our centre after a hospitalization for an acute IHD event and with no severe cognitive impairment are invited to the CRP; of them, those willing to participate are included in the programme.
As part of the programme activities, nurses educate patients in healthy habits during the in-hospital stage, as well as in follow-up visits at three and 12 months after discharge; provide and monitor quality of life, anxiety and depression symptoms using validated tests; and coordinate the follow-up plan and visits. Rehabilitation physicians and physiotherapists assess the functional status of the patient, promote and supervise the early mobilization and deambulation of patients during the hospital stay, and indicate and supervise physical activity during follow-up. All professionals involved in the CRP participate in monthly group sessions aimed at reinforcing the health education of the patients, with a special focus on increasing the patients' understanding of the pathophysiology of IHD, on the role of cardiovascular risk factors and on the importance of optimal risk factor management, particularly through physical activity, management of anxiety and adherence to guideline-recommended pharmacotherapies.
Because of its characteristics and infrastructure, the CRP provides thus an excellent platform to implement additional secondary prevention interventions.
Trial design and study participants
The Estudio de UTilización del chronic care model en pacientes isquémicos de Elevado Riesgo mediante un Proceso basado en Enfermería (EUTERPE, Spanish acronym) study was a single-centre, unblinded, randomized controlled pilot trial assessing the efficacy and safety of a specialized, nurse-guided, lipid-lowering intervention aimed at improving the management of LDL cholesterol levels and other cardiovascular risk factors in patients hospitalized for IHD.
Between 1 April 2012 and 28 February 2013, all patients hospitalized for IHD in our centre meeting inclusion criteria in the local CRP and willing to participate in the programme were screened for inclusion in this study. This included patients hospitalized for ST-segment elevation and non ST-segment elevation myocardial infarction, unstable angina and stable angina. Of them, all patients providing written informed consent were included in the EUTERPE. The study was approved by the Ethics Committee of the Hospital del Mar and was conducted in accordance with the Declaration of Helsinki.
Interventions. Participants were randomized in a 1:1 ratio to two management arms (Figure 1 ). The 'standard care arm' involved usual post-discharge follow-up, which in our healthcare area typically involves follow-up by the patient's primary care general physician, plus follow-up by a primary care cardiologist for a limited period of time; and inclusion in the standard CRP (see Study context above for more details).
On the other hand, the 'intervention arm' involved usual post-discharge follow-up, inclusion in the standard CRP, plus the following additional interventions: 1) periodic follow-up by a CRP nurse, who coordinated all 'intervention arm' actions; 2) conduct of serum lipid level controls at months 3 and 6 after discharge; 3) evaluation of laboratory test results using a pre-specified algorithm based on clinical practice guidelines and developed ad-hoc for this study (Supplementary Material Figure S1 online); 4) prescription and dispensing of any additional/alternative lipid lowering treatment, if indicated according to the algorithm, by a cardiologist involved in the CRP; and 5) permanent communication with the patient and with the patient's primary care physician (phone, email) regarding any laboratory test results and therapeutic changes during the intervention.
Randomization to the two study arms was performed using a computer-generated randomization scheme. Study participants and personnel were aware of, that is, not blinded to, the study intervention.
Study endpoints
The primary study endpoint was the proportion of patients with serum LDL cholesterol levels ⩽70 mg/dL at six months of follow-up in each study arm, which is the treatment goal supported by current ESC guidelines. 6, 8 Other variables related to lipid management assessed at six months included lipid-lowering medication use at six months, changes in lipid-lowering medication, changes in lipid levels as compared with hospital discharge, and proportion of individuals with a reduction in LDL cholesterol of ⩾50%, among others. Specifically, the atorvastatin equivalent daily dose was calculated using an equivalence chart generated by clinical pharmacy specialists.
As other secondary study endpoints, we also assessed the impact of the intervention in terms of control of other cardiovascular risk factors: proportion of patients with systolic blood pressure <140 mmHg and diastolic blood pressure <90 mmHg at six months; proportion of patients in which blood-pressure medication had changed at six months compared with discharge; levels of glycosylated haemoglobin (HbA1c); and proportion of active smokers (all after six months of follow-up). As tertiary study endpoints, we also assessed the frequency of urgent hospitalization and of all-cause death after six months of follow-up.
Because the safety of achieving LDL cholesterol levels <70 mg/dL and of aggressive LDL cholesterol management has been largely described in the literature, 2, 16, 17 no safety endpoints were evaluated in this pilot analysis.
Sample size
Although initially, based on sample size calculations, we aimed at recruiting 118 study participants (59 in each study arm), due to funding limitations the study population finally had to be restricted to 78 participants (39 in each study arm).
Statistical analyses
Baseline characteristics of the study participants were described using number and proportion for categorical variables, and median (interquartile range) for continuous variables. Differences between the two study arms were compared using chi-square statistics or Fisher's exact test for categorical variables, as needed, and non-parametric tests for continuous variables in order to account for the small sample size.
The same tests were used to compare the two study arms after six months of follow-up. For this comparison, an intention-to-treat analysis was performed. There were no losses to follow-up during the study period, and no cross-overs between study arms happened either.
The absolute atorvastatin dose change at six months and the absolute change in LDL cholesterol levels at six months was described graphically, for both study arms.
All statistical analyses were performed using Stata Version 15.0. 18 A p value of <0.05 was used to define statistical significance.
Results
Study participants
Between 1 April 2012 and 28 February 2013, 96 IHD patients discharged after an IHD-related hospitalization met the inclusion criteria of the CRP, and were therefore screened for inclusion in the study. Of them, 78 provided written informed consent, while 18 refused participation in the study. The 78 patients included in the study were randomized in a 1:1 ratio either to the standard care arm or to the study intervention arm (n = 39 each). 
Baseline characteristics
The baseline characteristics of the study participants (i.e. at hospital discharge) are summarized in Table 1 . Overall, the median age of the study population was 61 years, and 83% were male. There were no statistically significant differences between the two study groups in terms of baseline sociodemographic characteristics and other cardiovascular risk factors in the reason for hospitalization or in laboratory test results at admission. This included identical median baseline LDL cholesterol levels (103 mg/dL in both arms). There was a trend towards a higher median HbA1c in the intervention arm (6.1% as compared with 5.7% in the standard care arm) although this was not statistically significant.
At hospital discharge, 100% of patients in the intervention arm and 97.4% patients in the control arm received statins, with atorvastatin being the most frequently used option. The median equivalent daily dose of atorvastatin was identical in the two groups (40 mg per day). Table 2 summarizes the study results in terms of lipid management at six months after discharge. Briefly, although statin use remained very high in both study arms, the equivalent daily dose of atorvastatin was higher in the intervention group (Figure 2(a) ), and use of ezetimibe was more frequent among the patients in the intervention arm. Median total and LDL cholesterol levels were lower in the intervention arm, and the relative change in LDL cholesterol levels at six months was larger in the intervention arm than in the standard care arm (-36% reduction vs. -26% reduction, p 0.025). The distribution of absolute changes in LDL levels by study arm is presented in Figure 2 (b). In this context, the primary study endpoint (proportion of patients with LDL ⩽70 mg/dL at six months of follow-up) was achieved more frequently in the intervention arm (62%) than in the standard care arm (37%, p value 0.047). The less strict target of LDL cholesterol <100 mg/dL was achieved by 97.3% and 66.7% of participants, respectively (p<0.001). Also, a LDL cholesterol reduction of ⩾50% was more frequently attained in the intervention arm compared with the standard care arm (26% vs. 3%, p value 0.007). Table 3 summarizes the management of other relevant cardiovascular risk factors at six months of follow-up.
Lipid-lowering management and lipid level endpoints at six months of follow-up
Management of other cardiovascular risk factors
Compared with the standard care arm, there was a trend towards a better management of blood pressure levels in the intensive care arm compared with the standard care arm. These differences were statistically significant when only individuals with a prior diagnosis of hypertension were compared. On the other hand, no differences were observed between study arms with regard to tobacco use at six months or HbA1c levels. Table 3 also presents the results regarding urgent hospitalizations and all-cause death at six months of follow-up. During the study period, the number of hospitalizations was very few, and there were no deaths in any of the study arms. In this context, no statistically significant differences between the two study arms were identified.
Clinical events
Discussion
In this pilot, randomized, controlled trial conducted in a single centre in which a comprehensive CRP was in place, a nurse-led intervention including periodic followup, serial lipid level controls and subsequent optimization of lipid-lowering therapy, if appropriate, was associated with an improved management of LDL cholesterol levels compared with standard care alone. Also, the intervention was associated with improved blood pressure control among individuals with a diagnosis of hypertension. If replicated in larger studies, the present findings may have important implications for the chronic management of patients with IHD, in many of whom the treatment goals recommended by clinical practice guidelines are currently not achieved. In our study, despite being included in a comprehensive, multidisciplinary CRP, only 37% of the individuals in the standard care arm achieved the LDL target of ⩽70 mg/dL six months after discharge. This observation, which is consistent with the poor results published in the literature, 6, 7 highlights the need for additional efforts aimed at improving adherence to and treatment titration of lipid-lowering medications in patients with IHD. Of note, despite the additional interventions included in the intervention arm, 38% of participants in this group still did not achieve the LDL ⩽70 mg/dL target, which stresses the complexity of the issue and the difficulty of achieving full success in this patient population.
Our results are consistent with those from prior studies assessing the efficacy of nurse-led cardiovascular risk reduction programmes in patients with IHD. In the Randomised Evaluation of Secondary Prevention by Outpatient Nurse SpEcialists (RESPONSE) trial, 19, 20 which included 754 patients from The Netherlands admitted for an acute coronary syndrome and exposed to a nurse-coordinated secondary prevention intervention (comprising four outpatient clinic visits to a cardiovascular nurse focused on healthy lifestyle recommendations, improvement of biometric risk factors and of medication adherence, and in which medication adjustment was conducted when necessary), there was a significant improvement in overall cardiovascular risk factor control, in 10-year estimated cardiovascular disease death risk after 12 months, and in re-hospitalizations among individuals exposed to the intervention as compared with those in the usual care arm. Specifically regarding LDL cholesterol, although study nurses had been trained and were highly confident about their ability to achieve drug-related treatment targets, 21 differences between the two study arms were smaller than in our study, with a target of LDL cholesterol <2.5 mmol/L (≈100 mg/dL) being achieved in 80% of patients in the intervention arm compared with 69% in the usual care arm (as compared with 97% and 67%, respectively, in our study). Our results are also consistent with those from observational studies evaluating similar nurse-led programmes, 22, 23 as well as with experimental evaluations conducted in other groups of cardiovascular patients. 15 In this context, to our knowledge our analysis is the first to assess the efficacy of a nurse-based intervention in terms of achieving the LDL target recommended in the 2016 ESC guidelines, 6 as well as in terms of achieving the LDL reduction recommended in the 2013 American College of Cardiology/American Heart Association cholesterol treatment guidelines. 24 Our findings have important clinical implications. The intervention, which could be easily incorporated into a standard CRP, resulted not only in clear benefits in terms of lipid level management, but also in improved management of blood pressure levels among individuals with hypertension. Because the intervention did not include any actions aimed at modifying the patient's blood pressure lowering pharmacologic treatment, the latter was likely the consequence of the increased contact between the healthcare personnel and patients leading to greater adherence to healthy lifestyle recommendations. Our study identifies thus an invaluable opportunity to improve the secondary prevention management of patients with IHD.
Study limitations
Some study limitations must be acknowledged. First, patients were recruited from a single medical centre, therefore, generalizability of our findings to other patient populations and healthcare environments may be limited. Nevertheless, the benefits of closer follow-up observed in our study are likely to apply to other environments. Second, the small sample size may have impacted statistical power and our ability to identify statistically significant differences between the groups. This, however, did not prevent observing significant differences between the study arms in several endpoints, including the prespecified primary study endpoint, which supports the efficacy of the intervention. On the other hand, our analysis was clearly underpowered to identify differences in clinical events, or in other study endpoints such as differences in tobacco use during follow-up. Third, the small sample size also prevented conducting detailed evaluations of different lipid-lowering pharmacologic management strategies. For the same reason, subgroup analyses in clinically relevant subgroups of patients were not feasible either. Finally, because the study was conducted before 2015, this prevented gaining insights on the effectiveness specifically of PCSK9 inhibitors 25 in patients with IHD. These limitations stress the pilot nature of the present analysis, and the need to replicate our findings in larger, multi-centre, contemporary cohorts.
Conclusions
In this small experimental study, a nurse-led intervention added to a standard CRP including periodic follow-up, serial lipid level checks and subsequent optimization of lipid-lowering therapy was associated with a markedly improved management of LDL cholesterol levels compared with a standard CRP programme alone. Our findings highlight the opportunity that nurse-led, intensive, postdischarge follow-up plans represent for the optimization of risk factor control and specifically of LDL cholesterol in patients with IHD.
Implications for practice
• • Strategies are needed to optimize secondary prevention in post-myocardial infarction patients; • • A nurse-led intervention improved low-density lipoprotein cholesterol control at six months; • • Other risk factor-control benefits were also observed at six months; • • Easily incorporable to a standard rehabilitation programme.
